Home » Biotechnology » Plasma Fractionation Market

Plasma Fractionation Market By Product (Coagulation Factor Concentrates, Immunoglobulin, Albumin, Protease Inhibitors and Others), By Application (Neurology, Immunology, Hematology, Critical Care and Others) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Market Insights:

The plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2018 to 2026, from US$ 18,099.5 million in 2017 to US$ 33,386.6 million by 2026. Plasma fractionation is utilized for obtaining large quantities of purified protein from human plasma. Researchers have been focusing diligently on understanding the role and significance of plasma-derived proteins in treating chronic ailments and autoimmune diseases. Increasing demand for biologics and increasing healthcare expenditure for drug development activities together drive the plasma fractionation market’s growth.

The rising prevalence of autoimmune disorders and technical innovation in deriving highly purified proteins from human plasma drive the immunoglobulin market’s growth.

Immunoglobulins are the market’s dominant product segment in plasma fractionation. Technical innovations in deriving highly purified proteins from human plasma and the rising prevalence of autoimmune disorders drive the immunoglobulin market’s growth. They are primarily composed of five classes (D, G, M, A, and E) and several subclasses that are responsible for immune system consolidation. Albumin is gaining huge attention among researchers owing to its drug-binding properties and its effective use as a formulating drug agent, medical device coating, surgery sealant, and vaccine ingredient.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Increasing morbidity and a lack of effective biological treatment drive the neurology applications market’s growth.

According to the World Health Organization (WHO), approximately 450 million people are reported to be suffering from mental illness each year. Neurology is dominating the application segment for the plasma fractionation market. The chief attributes governing its market growth are increasing morbidity and the lack of effective biological treatment for neurological disorders. Recently, newer antibodies have been developed to hinder the process of protein cluster misfolding, which causes Alzheimer’s and Parkinson’s diseases. Immunology applications will be the fastest-growing segment in the near future owing to the significant rise in immunocompromised patients and technological advancements in the development of immunoglobulin to counteract disease manifestations associated with immunosuppression.

The increasing number of patients suffering from chronic diseases and the presence of state-of-the-art healthcare infrastructure drive market growth in North America.

North America is the supreme leader in the global plasma fractionation market, representing 38% of its share. The dominance is attributed to major factors such as the increasing number of patients suffering from chronic diseases and the presence of state-of-the-art healthcare infrastructure. As per the statistics provided by the Centers for Disease Control and Prevention (CDC), 1 in every 6 Americans is living with a chronic disease.

Europe holds a 25% market share owing to the existence of key players such as Biotest AG, Sanquin, Octapharma AG, and Grifols S.A. and the supportive regulatory environment provided by the European Medical Agency (EMA). Asia Pacific is responsible for 17% of the market’s share and will showcase impressive growth during the forecast period on account of a rise in per capita income and an affordable reimbursement scenario for plasma fractionation products utilized during the treatment of chronic ailments.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026,considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by product, application, and geography.

Biopharmaceuticals actively engaged in providing plasma fractionation products are Baxter International, Inc., Biotest AG, CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG, Sanquin, and Shire, Plc.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

What are the latest inorganic and organic market growth strategies adopted in the plasma fractionation market?
Which biopharmaceutical companies are providing plasma-fractionated products for treating chronic ailments?
What are the latest technical innovations associated with human plasma protein purification?
What is the clinical use of immunoglobulin?
What are the prevalence rate of neurological disorders and their treatment using antibodies?
What is the growth rate of the plasma fractionation market in developing countries such as Asia Pacific, Latin America, the Middle East, and Africa?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global PF Market Portraiture
2.2. Global PF Market, by Product, 2017 (US$ Mn)
2.3. Global PF Market, by Application, 2017 (US$ Mn)
2.4. Global PF Market, by Geography, 2017 (US$ Mn)

Chapter 3. Plasma Fractionation (PF) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global PF Market, by Key Players, 2017

Chapter 4. Global Plasma Fractionation (PF) Market, by Product
4.1. Overview
4.2. Coagulation Factor Concentrates
4.3. Immunoglobulin
4.4. Albumin
4.5. Protease Inhibitors
4.6. Others

Chapter 5. Global Plasma Fractionation (PF) Market, by Application
5.1. Overview
5.2. Neurology
5.3. Immunology
5.4. Hematology
5.5. Critical Care
5.6. Others

Chapter 6. Global Plasma Fractionation (PF) Market, by Geography
6.1. Overview
6.2. North America PF Market Analysis, 2016 – 2026
6.2.1. North America PF Market, by Product, 2016 – 2026 (US$ Mn)
6.2.2. North America PF Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America PF Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe PF Market Analysis, 2016 – 2026
6.3.1. Europe PF Market, by Product, 2016 – 2026 (US$ Mn)
6.3.2. Europe PF Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific PF Market Analysis, 2016 – 2026
6.4.1. Asia Pacific PF Market, by Product, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific PF Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America PF Market Analysis, 2016 – 2026
6.5.1. Latin America PF Market, by Product, 2016 – 2026 (US$ Mn)
6.5.2. Latin America PF Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Latin America PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa PF Market Analysis, 2016 – 2026
6.6.1. MEA PF Market, by Product, 2016 – 2026 (US$ Mn)
6.6.2. MEA PF Market, by Application, 2016 – 2026 (US$ Mn)
6.6.3. MEA PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Baxter International, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Biotest AG
7.3. CSL Limited
7.4. Grifols, S.A.
7.5. Green Cross Corporation
7.6. Japan Blood Products Organization
7.7. Kedrion Biopharma, Inc.
7.8. Octapharma AG
7.9. Sanquin
7.10. Shire, Plc.

List of Figures

FIG. 1 : Plasma Fractionation (PF) Market: Research Methodology
FIG. 2 : PF: Market Segmentation
FIG. 3 : Global PF Market, by Product, 2017 (US$ Mn)
FIG. 4 : Global PF Market, by Application, 2017 (US$ Mn)
FIG. 5 : Global PF Market, by Geography, 2017 (US$ Mn)
FIG. 6 : Attractive Investment Proposition: by Geography, 2017
FIG. 7 : Competitive Analysis: Global PF Market, by Key Players, 2017
FIG. 8 : Global Coagulation Factor Concentrates Market for PF, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Immunoglobulin Market for PF, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Albumin Market for PF, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Protease Inhibitors Market for PF, 2016 – 2026 (US$ Mn)
FIG. 12 : Global Other Products Market for PF, 2016 – 2026 (US$ Mn)
FIG. 13 : Global Neurology Market for PF, 2016 – 2026 (US$ Mn)
FIG. 14 : Global Immunology Market for PF, 2016 – 2026 (US$ Mn)
FIG. 15 : Global Hematology Market for PF, 2016 – 2026 (US$ Mn)
FIG. 16 : Global Critical Care Market for PF, 2016 – 2026 (US$ Mn)
FIG. 17 : Global Other Applications Market for PF, 2016 – 2026 (US$ Mn)
FIG. 18 : U.S. PF Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Canada PF Market, 2016 – 2026 (US$ Mn)
FIG. 20 : U.K. PF Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Germany PF Market, 2016 – 2026 (US$ Mn)
FIG. 22 : Rest of Europe PF Market, 2016 – 2026 (US$ Mn)
FIG. 23 : China PF Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Japan PF Market, 2016 – 2026 (US$ Mn)
FIG. 25 : Rest of Asia Pacific PF Market, 2016 – 2026 (US$ Mn)
FIG. 26 : Brazil PF Market, 2016 – 2026 (US$ Mn)
FIG. 27 : Mexico PF Market, 2016 – 2026 (US$ Mn)
FIG. 28 : Rest of Latin America PF Market, 2016 – 2026 (US$ Mn)
FIG. 29 : GCC PF Market, 2016 – 2026 (US$ Mn)
FIG. 30 : Rest of MEA PF Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 : Global Plasma Fractionation (PF) Market Portraiture
TABLE 2 : Global PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 3 : Global PF Market , by Application, 2016 – 2026 (US$ Mn)
TABLE 4 : Global PF Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 : North America PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 6 : North America PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 7 : North America PF Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 : Europe PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 9 : Europe PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 10 : Europe PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 : Asia Pacific PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 12 : Asia Pacific PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 13 : Asia Pacific PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 : Latin America PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 15 : Latin America PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 16 : Latin America PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 : Middle East and Africa PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 18 : Middle East and Africa PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 19 : Middle East and Africa PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 : Baxter International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Biotest AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : CSL Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Grifols, S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 : Green Cross Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 : Japan Blood Products Organization: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 : Kedrion Biopharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 : Octapharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 : Sanquin: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 : Shire, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Question:

What is the size of Plasma Fractionation Market?

The market for Plasma Fractionation Market is expected to reach USD$ 33,386.6 Mn in 2026.

What is the size of Plasma Fractionation Market?

The Plasma Fractionation Market is expected to see significant CAGR growth over the coming years, at 7.1%

What is the Forecast period considered for Plasma Fractionation Market?

The report is forecasted from 2018 -2026.

What is the base year considered for Plasma Fractionation Market?

The base year of this report is 2017.

Who are the major players in this market?

Biotest AG, CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –